Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

VR headset teaches breast cancer survivors about heart risks

NCT ID NCT07426913

Knowledge-focused Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a virtual reality program called SurviVRSE that teaches breast cancer survivors about heart health. Thirty women currently receiving certain cancer treatments will use the VR headset during one infusion session. Researchers will measure how much they learn, how easy the system is to use, and whether they find it helpful.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
virtual reality education program
What this could lead to
If successful, this VR program could become a tool to help breast cancer survivors learn about heart risks and adopt healthier habits.
What could go wrong
This is a small, early-phase study focused on feasibility, not on proving health outcomes. The results may not apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Able to speak and read in English * Actively receiving Trastuzumab or an anthracycline-based treatment * Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab. * Diagnosed with stages 0-III Breast Cancer Exclusion Criteria: \- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anthracycline related cardiotoxicity in breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cardiomyopathy due to anthracyclines

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anthracycline related cardiotoxicity in breast cancer Breast cancer Trastuzumab Virtual reality

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Adult Outpatient Pavilion

    RECRUITING

    Richmond, Virginia, 23220, United States

  • Cellular Immunotherapies and Transplant Department

    RECRUITING

    Richmond, Virginia, 23220, United States

  • VCU Health at Stony Point

    RECRUITING

    Richmond, Virginia, 23223, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.